Literature DB >> 20362285

The safety and probable therapeutic effect of routine use of antibiotics and simultaneously treating bleeding gastric varices by using endoscopic cyanoacrylate injection and concomitant esophageal varices with banding ligation: a pilot study.

Chen-Jung Chang1, Ming-Chih Hou, Han-Chieh Lin, Hai-Shin Lee, Wei-Chih Liao, Chien-Wei Su, Shou-Dong Lee.   

Abstract

BACKGROUND: Gastroesophageal varices are the most common type of gastric varices. Although endoscopic injection of N-butyl-2-cyanoacrylate is the current treatment of choice for acute gastric variceal bleeding, whether the concomitant esophageal varices should be ligated simultaneously with the first treatment session is currently not known.
OBJECTIVE: The aim of this study was to evaluate the safety and probable therapeutic effect of simultaneous cyanoacrylate injection for bleeding gastric varices obliteration (GVO) and endoscopic band ligation (EBL) for concomitant esophageal varices in combination with routine antibiotics (simultaneous group), and to compare our results with historical results in which the patients underwent GVO first and then EBL for concomitant esophageal varices (separate group).
DESIGN: A single-center pilot study.
SETTING: A tertiary referral center. PATIENTS: Patients with liver cirrhosis and gastroesophageal varices, who presented with acute gastric varices bleeding.
INTERVENTIONS: Simultaneous treatment in the form of GVO and EBL for concomitant esophageal varices in combination with routine antibiotics. MAIN OUTCOME MEASUREMENT: Rebleeding and mortality within the first year of index bleeding.
RESULTS: Twenty patients in the simultaneous group and 67 patients in the separate group were included in the study. The 2 groups had similar baseline characteristics. The hemostasis of active bleeding was 100% in both groups (7/7 vs 20/20). The 1-year rebleeding rate was 10% (2/20) in the simultaneous group and 37.31% (25/67) in the separate group (P = .041). Kaplan-Meier analysis showed higher probability of remaining free of rebleeding in the simultaneous group (88.5% vs 61.1%; P = .044). Multivariate analysis indicated that treatment method (separate group) and high model for end-stage liver disease score (> or = 13) were independent risk factors of rebleeding in 1 year. The treatment failure, complications, 1-year mortality, and survival were similar in both groups.
CONCLUSION: Simultaneous endoscopic treatment for gastric varices bleeding and concomitant esophageal varices is a safe and effective procedure in combination with antibiotic prophylaxis for patients with cirrhosis. The 1-year mortality rate was similar between the 2 groups. The results need further validation. Copyright 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20362285     DOI: 10.1016/j.gie.2009.12.010

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  4 in total

1.  Repeated pancreatitis-induced splenic vein thrombosis leads to intractable gastric variceal bleeding: A case report and review.

Authors:  Shan-Hong Tang; Wei-Zheng Zeng; Qian-Wen He; Jian-Ping Qin; Xiao-Ling Wu; Tao Wang; Zhao Wang; Xuan He; Xiao-Lei Zhou; Quan-Shui Fan; Ming-De Jiang
Journal:  World J Clin Cases       Date:  2015-10-16       Impact factor: 1.337

Review 2.  Role of prophylactic antibiotics in cirrhotic patients with variceal bleeding.

Authors:  Yeong Yeh Lee; Hoi-Poh Tee; Sanjiv Mahadeva
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

3.  Cyanoacrylate: a handy tissue glue in maxillofacial surgery: our experience in alexandria, egypt.

Authors:  Ahmed Habib; Ahmed Mehanna; Ahmed Medra
Journal:  J Maxillofac Oral Surg       Date:  2012-09-15

4.  Efficacy of Endoscopic Intervention plus Growth Inhibitor and Patient Self-Management in the Treatment of Esophagogastric Variceal Bleeding in Cirrhosis.

Authors:  Zhaoyun Yang; Yizhen Wang; Qin Yu; Shouli Wang; Derun Kong
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-15       Impact factor: 2.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.